Forte Biosciences (FBRX) Cash from Operations (2016 - 2020)
Historic Cash from Operations for Forte Biosciences (FBRX) over the last 5 years, with Q4 2020 value amounting to -$3.8 million.
- Forte Biosciences' Cash from Operations fell 48238.9% to -$3.8 million in Q4 2020 from the same period last year, while for Dec 2020 it was -$18.4 million, marking a year-over-year decrease of 56485.02%. This contributed to the annual value of -$30.7 million for FY2024, which is 710.3% down from last year.
- Forte Biosciences' Cash from Operations amounted to -$3.8 million in Q4 2020, which was down 48238.9% from -$7.7 million recorded in Q3 2020.
- Forte Biosciences' 5-year Cash from Operations high stood at $16.1 million for Q2 2019, and its period low was -$17.7 million during Q1 2019.
- Moreover, its 5-year median value for Cash from Operations was -$7.5 million (2017), whereas its average is -$5.8 million.
- As far as peak fluctuations go, Forte Biosciences' Cash from Operations skyrocketed by 24974.45% in 2019, and later crashed by 129945.75% in 2020.
- Forte Biosciences' Cash from Operations (Quarter) stood at -$7.7 million in 2016, then decreased by 18.38% to -$9.2 million in 2017, then plummeted by 30.21% to -$11.9 million in 2018, then skyrocketed by 94.53% to -$653000.0 in 2019, then plummeted by 482.39% to -$3.8 million in 2020.
- Its Cash from Operations was -$3.8 million in Q4 2020, compared to -$7.7 million in Q3 2020 and -$4.0 million in Q2 2020.